Document Detail


Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness.
MedLine Citation:
PMID:  8875954     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To measure the effects of skin disease on patients' quality of life, we developed a 61-item self-administered survey instrument called Skindex. Skindex has eight scales, each of which addresses a construct, or an abstract component, in a comprehensive conceptual framework: cognitive effects, social effects, depression, fear, embarrassment, anger, physical discomfort, and physical limitations. Item responses are standardized from 0 (no effect) to 100 (maximal effect); a scale score is the average of responses to items addressing a construct. In 201 patients seen by dermatologists, mean scale scores (+/-SD) ranged from 14 (+/-17) for physical limitations to 31 (+/-22) for physical discomfort. Scale scores were reproducible after 72 h (r = 0.68-0.90) and were internally consistent (Cronbach's alpha = 0.76-0.86). Construct validity was assessed in two ways: (i) in a comparison of patients with inflammatory dermatoses and patients with isolated lesions, patients with inflammatory dermatoses had higher scale scores, and (ii) in an exploratory factor analysis, 78% of the common variance was explained by seven factors that correlated with the scale scores of Skindex. Most of the a priori scale scores changed in the expected direction in patients who reported that their skin conditions had improved or worsened after 6 mo. Finally, physicians' judgments of disease severity did not consistently correlate with Skindex scores. These preliminary data suggest that Skindex reliably and responsively measures the effects of skin disease on patients' quality of life and may supplement clinical judgments of disease severity.
Authors:
M M Chren; R J Lasek; L M Quinn; E N Mostow; S J Zyzanski
Related Documents :
10870074 - The schedule of attitudes toward hastened death: measuring desire for death in terminal...
11248534 - The a-b neuropsychological assessment schedule (abnas): the further refinement of a pat...
10877234 - Patient-based assessment in dyspepsia: development and validation of dyspepsia symptom ...
23986724 - Electroconvulsive treatment: hypotheses about mechanisms of action.
22028424 - Rosiglitazone and pioglitazone for the treatment of alzheimer's disease (november).
15556124 - Antidepressant treatment of co-occurring depression and alcohol dependence.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The Journal of investigative dermatology     Volume:  107     ISSN:  0022-202X     ISO Abbreviation:  J. Invest. Dermatol.     Publication Date:  1996 Nov 
Date Detail:
Created Date:  1996-11-27     Completed Date:  1996-11-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0426720     Medline TA:  J Invest Dermatol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  707-13     Citation Subset:  IM    
Affiliation:
Department of Dermatology, University Hospitals of Cleveland and Case Western Reserve University, Ohio, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Female
Humans
Male
Middle Aged
Quality of Life*
Reproducibility of Results
Skin Diseases / psychology*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mutations in the ligand-binding domain of the kit receptor: an uncommon site in human piebaldism.
Next Document:  Topical retinaldehyde increases skin content of retinoic acid and exerts biologic activity in mouse ...